Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22831369 | 0.91 | MAPT (0.62) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL3922203 | 0.89 | MAPT (0.60) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL14831492 | 0.82 | MAPT (0.53) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL30935134 | 0.81 | MAPT (0.51) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL30040581 | 0.81 | MAPT (0.51) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL19860565 | 0.81 | MAPT (0.51) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL13095989 | 0.80 | MAPT (0.55) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL22831325 | 0.79 | KCNH2 (0.53) | MAPTCHRNB2CHRNA4ALDH1A1MEN1 | |
| SCHEMBL24233867 | 0.79 | MAPT (0.79) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 | |
| SCHEMBL17571472 | 0.79 | MAPT (0.53) | MAPTKEAP1NFE2L2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | MAPT 2899/4885KEAP1 1325/4885NFE2L2 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.